Source-grounded facts extracted from Beneficient's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Beneficient: Filed a certificate of designation for Series B-10 Preferred Stock, designating rights, preferences, privileges, and restrictions (effective 2026-04-08).
“On April 8, 2026, the Company filed a certificate of designation (the “B-10 Certificate of Designation”) with the Secretary of State of Nevada, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the shares of the Series B-10 Preferred Stock.”
Beneficient amended Letter Agreement with HH-BDH, LLC valued at $1.66 million (effective 2026-03-10).
“On March 10, 2026, HH-BDH and the Loan Parties entered into that certain Letter Agreement (the “Letter Agreement”), pursuant to which the Credit Agreement was amended to provide for the payment of the remaining $1.66 million in interest and fees outstanding under the Credit Agreement.”
Beneficient: Filed a certificate of designation for Series B-9 Preferred Stock, setting terms including conversion rights, price reset, and ranking (effective 2026-01-05).
“On January 5, 2026, the Company filed a certificate of designation (the “B-9 Certificate of Designation”) with the Secretary of State of Nevada, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the shares of the Series B-9 Preferred Stock.”
Beneficient: Approved a 1-for-8 reverse stock split and proportionate reduction in authorized shares of Class A and Class B common stock, effective December 15, 2025 (effective 2025-12-15).
“On December 10, 2025, the Company filed a Certificate of Change with the Secretary of State of the State of Nevada to effect the Reverse Stock Split at a ratio of 1-for-8 and a simultaneous proportionate reduction in the authorized shares of each class of Common Stock. The Reverse Stock Split is expected to become effective at 12:01 a.m. Eastern Time on December 15, 2025 (the “Effective Time”).”
Beneficient received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“October 3, 2025, Beneficient (the “Company”) was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that because the Company’s Form 10-K for the fiscal year ended March 31, 2025 reported a stockholders’ equity of ($34,925,000), the Company was in non-compliance with the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”), which could also serve as a separate and additional basis for delisting in addition to the matters described below (such letter, the “Additional Determination Le”
Beneficient received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 17, 2025, the Company received a letter (the “January 2025 Notice”) from Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) because the bid price for the Company’s Class A common stock had closed below the $1.00 per share minimum threshold required for continued listing on The Nasdaq Capital Market for the previous 30 consecutive business days. The January 2025 Notice provided the Company a 180-calendar day period to regain compliance with the Bid Price Requirement, through July 14, 2025. As also previously disclosed”
Beneficient received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“August 18, 2025, Beneficient (the “Company”) was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 with the Securities and Exchange Commission (the “SEC”), the Company was in non-compliance with the periodic reporting requirement set forth in Nasdaq Listing Rule 5250(c)(1) (the “Filing Requirement”), which could also serve as a separate and additional basis for delisting in addition to the issues described below (such letter, the “Additional”
Beneficient reported a default on credit facility of $11.6 million (including an unamortized discount thereon) of debt outstanding derived from the term loan with HH-BDH with HH-BDH LLC.
“(“Ben Financing”), and BCH, as guarantor, and HH-BDH, as administrative agent (as amended, the “HH-BDH Credit Agreement”). As of June 30, 2025, Ben Financing had approximately $11.6 million (including an unamortized discount thereon) of debt outstanding derived from the term loan with HH-BDH. The HH-BDH Credit Agreement provides that the occurrence of an event of”
Beneficient reported a default on credit facility of $94.4 million (including an unamortized premium thereon) of debt outstanding derived from the loans pursuant to the Cred with HCLP Nominees, L.L.C. at 11.5% per annum.
“Agreement, after as well as before judgment, at a rate equal to 11.5% per annum and such accrued interest shall be payable on demand. As of June 30, 2025, BCH had approximately $94.4 million (including an unamortized premium thereon) of debt outstanding derived from the loans pursuant to the Credit Agreements. In addition, unpaid interest of $20.8 million was accrued”
Beneficient received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).
“ny has not yet filed its Annual Report on Form 10-K for the fiscal year ending March 31, 2025 with the Securities and Exchange Commission and, as such, the Determination Letter also notified the Company that its non-compliance with the periodic reporting requirement set forth in Nasdaq Listing Rule 5250(c)(1) (the “ Filing Requirement ”) could serve as a separate and additional basis for delisting. In addition to the Company’s request for a hearing before the Panel and in accordance with Nasdaq Listing Rule 5815(a)(1), the Company also plans to timely submit a request for a further extension o”
Beneficient received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“ny has not yet filed its Annual Report on Form 10-K for the fiscal year ending March 31, 2025 with the Securities and Exchange Commission and, as such, the Determination Letter also notified the Company that its non-compliance with the periodic reporting requirement set forth in Nasdaq Listing Rule 5250(c)(1) (the “ Filing Requirement ”) could serve as a separate and additional basis for delisting. In addition to the Company’s request for a hearing before the Panel and in accordance with Nasdaq Listing Rule 5815(a)(1), the Company also plans to timely submit a request for a further extension o”
Beneficient: Filed Series B-8 Certificate of Designation designating rights, preferences, and restrictions of Series B-8 Preferred Stock (effective 2025-06-17).
“On June 17, 2025, the Company filed a certificate of designation (the “B-8 Certificate of Designation”) with the Secretary of State of Nevada, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the shares of the Series B-8 Preferred Stock.”
Beneficient received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 13, 2025, Beneficient (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previo”
Karen Wendel was appointed as Director at Beneficient.
“On November 21, 2024, the board of directors (the “Board”) of the Company appointed Karen Wendel to serve as a director of the Company, effective November 21, 2024.”
Patrick J. Donegan was appointed as Director at Beneficient.
“On September 30, 2024, the board of directors (the “Board”) of the Company appointed Patrick J. Donegan to serve as a director of the Company, effective September 30, 2024.”
Dennis P. Lockhart resigned as Member of the Board and the Audit Committee at Beneficient.
“Also on July 19, 2024, Dennis P. Lockhart resigned as a member of the Board and the Audit Committee effective immediately (the "Lockhart Resignation" and together with the Hill Resignation, the "Resignations").”
Emily B. Hill resigned as Member of the Board and the Audit Committee at Beneficient.
“On July 19, 2024, Emily B. Hill delivered notice of resignation as a member of the Board and the Audit Committee effective September 30, 2024 (the "Hill Resignation").”
James G. Silk resigned as Executive Vice President and Chief Legal Officer at Beneficient.
“On April 29, 2024, James G. Silk resigned as a member of the Board of Directors (the “Board”) of Beneficient (the “Company” or “Ben”) and from his role as Executive Vice President and Chief Legal Officer of the Company effective May 10, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.